Irreversible electroporation for pancreatic cancer

Irreversible electroporation (IRE) is a treatment that uses electrical currents to damage and destroy the cancer cells. It is also called NanoKnife®.

What's in the 'IRE' section?


Key facts

  • During IRE treatment, needles are put in around the cancer. Electrical currents are then passed between the needles. These currents damage and destroy the cancer cells.
  • NanoKnife® is the brand name for the machine used to deliver the treatment.
  • There has not been much research into IRE for pancreatic cancer, so we only have limited information about how well it works.
  • The National Institute for Health and Care Excellence (NICE) says that IRE should only be used in research looking at how well it works for pancreatic cancer.
  • IRE may be suitable for some people with locally advanced pancreatic cancer. This is cancer that has spread just outside the pancreas, and can’t usually be removed with surgery.
  • IRE may also be offered to a few people with borderline resectable pancreatic cancer where surgery to remove the cancer may be possible. IRE may be used to treat the cells around the edges of the tumour. The aim is to make removing the cancer as successful as possible. There is not much evidence on IRE used in this way, and we need more research into this.
  • IRE aims to slow the growth of pancreatic cancer. This may help some people with locally advanced or borderline resectable cancer to live longer. It may also help treat symptoms such as pain.
  • Before having IRE you will normally have three to six months of chemotherapy .
  • IRE can cause side effects such as pain, feeling and being sick, and heartburn. These side effects don’t usually last long.
  • IRE can cause other side effects, such as inflammation of the pancreas (pancreatitis)or more rarely, a blood clot in a vein.
  • As there isn’t much research into IRE, if you are thinking about having it it’s really important you speak to your doctor before making any decisions.

Research on IRE for pancreatic cancer

There has not been much research into IRE for people with pancreatic cancer. This means that we don’t know enough about how well it works, who it is most suitable for, and the side effects and complications.

The National Institute for Health and Care Excellence (NICE) has said that IRE should only be used in research. Researchers are setting up a clinical trial in the UK to look at IRE for pancreatic cancer. We will provide information about the trial when it’s available on our Trial Finder . Until there is a clinical trial available, NHS hospitals that provide IRE are collecting information about how well it works.

Read more about clinical trials for pancreatic cancer .

As there isn’t much research into IRE, make sure you speak to your doctor before making any decisions about having it. Ask them any questions you might have about IRE, including whether it is suitable for you, how effective it is, and the possible side effects. You can find more questions below. Don’t stop any treatment while you are thinking about having IRE.

Questions to ask your doctor or nurse


  • Is IRE an option for me?
  • If it is an option, how can I access it?
  • What does IRE involve?
  • Will IRE help me to live longer?
  • Will IRE make surgery more likely?
  • Will IRE help any of my symptoms?
  • What treatment will I need beforehand?
  • What will happen during the treatment?
  • Will I need to stay in hospital after the treatment?
  • What side effects am I likely to have?
  • How long will the side effects last and how can they be managed?
  • Will I need further treatment after IRE?

Read our fact sheet about irreversible electroporation (IRE)

To read more about irreversible electroporation (IRE), download our fact sheet, Irreversible electroporation (IRE) for pancreatic cancer.

Download our fact sheet
Front page of factsheet

Speak to our specialist nurses

You can speak to our specialist nurses on our free Support Line for more information about IRE.

Speak to our nurses
Specialist nurse Nicci

References and acknowledgements


References

If you would like the references to the sources used to write this information, email us at publications@pancreaticcancer.org.uk

Acknowledgements

We would like to thank the following people who reviewed this information:

  • Brian R Davidson, Consultant HPB and Liver Transplant Surgeon, Royal Free London NHS Foundation Trust and Wellington Hospitals
  • Nicola de’ Liguori Carino, Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary
  • Peter Littler, Consultant Interventional Radiologist, Newcastle Hospitals NHS Foundation Trust
  • Pancreatic Cancer UK Lay Information Reviewers
  • Pancreatic Cancer UK Specialist Nurses

Updated: June 2023

To be reviewed: June 2025